144
edits
CPVT: Difference between revisions
m
→Medication/Other therapies:
No edit summary |
|||
| Line 47: | Line 47: | ||
*β-blockers are first line therapy in CPVT because of their sympatholytical effect. However, β-blockers are not fully protective in all CPVT patients. | *β-blockers are first line therapy in CPVT because of their sympatholytical effect. However, β-blockers are not fully protective in all CPVT patients. | ||
*Flecainide<cite>flecainide</cite> can be given to CPVT patients with refractory ventricular ectopy despite β-blocker therapy. Flecainide directly blocks RyR2 channels. | *Flecainide<cite>flecainide</cite> can be given to CPVT patients with refractory ventricular ectopy despite β-blocker therapy. Flecainide directly blocks RyR2 channels. | ||
*Left cardiac sympathetic denervation can be done in selected patients and largely prevents norepinephrine release in the heart and may therefore reduce adrenergically mediated arrhythmias. | *Left cardiac sympathetic denervation<cite>Wilde</cite> can be done in selected patients and largely prevents norepinephrine release in the heart and may therefore reduce adrenergically mediated arrhythmias. | ||
*The need for ICD therapy needs careful judgement since ICDs might not offer the ultimate protection in CPVT because of the fact that both appropriate and inappropriate shocks can trigger catecholamine release, resulting in arrhythmic ICD storms and death. | *The need for ICD therapy needs careful judgement since ICDs might not offer the ultimate protection in CPVT because of the fact that both appropriate and inappropriate shocks can trigger catecholamine release, resulting in arrhythmic ICD storms and death. | ||
==References== | ==References== | ||